Clinical Trial Update: Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 [Phase 1]

View source ↗

Summary

A Phase 1 study to evaluate the safety and tolerability of VK2735 in obesity/weight management and nonalcoholic steatohepatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis
• Obesity

Drugs mentioned

• VK2735

Snippet

Sponsor: Viking Therapeutics, Inc. | Conditions: Weight Loss, NASH | Phase 1 | Status: COMPLETED